December 9th 2017, 1:11am
Losing even a moderate amount of extra weight significantly reduces the risk of breast cancer for postmenopausal women, a researcher reports.
December 9th 2017, 12:52am
The incidence of human papillomavirus-related oropharyngeal cancer (HPV-OPC) is on the rise. Researchers at Johns Hopkins University assessed survey data to determine whether the risk among the general population is rising as well. Results show that for most people, the risk remains low.
December 9th 2017, 12:30am
Talazoparib, a PARP inhibitor is more effective than chemotherapy in reducing the risk of disease progression and death from BRCA-positive breast cancer.
December 8th 2017, 3:00am
Researchers find that women with postmenopausal hormone receptor (HR)-positive breast cancer may undergo shorter treatments of Arimidex, which may in turn cause less bone fractures.
December 8th 2017, 1:50am
A phase 3 clinical trial pitted a nine-week treatment of adjuvant Herceptin against the regimen of a full year of treatment for patients with HER2-positive breast cancer. Results show that the standard treatment of one year is still optimal.
December 7th 2017, 11:49pm
To address compliance issues associated with treatment using aromatase inhibitors, researchers show that acupuncture effectively eases joint pain, a side effect from hormone therapy.
December 7th 2017, 10:36pm
A reveiw of five clinical trial findings suggests that gonadotropin-releasing hormone analog has the potential to preserve ovarian function and fertility in premenopausal breast cancer patients.
December 7th 2017, 8:17pm
New research demonstrates that a CDK4/6 inhibitor, used in combination with standard endocrine therapy with temporary ovarian suppression significantly improves progression-free survival in younger patients who currently have few treatment options.
December 7th 2017, 3:30am
The combination of Keytruda (pembrolizumab) and Herceptin (trastuzumab) showed promise for the treatment of women with Herceptin-resistant, PD-L1–positive, HER2-positive breast cancer.
December 7th 2017, 1:55am
A stud presented at SABCS shows that IMMU-132, an antibody-drug conjugate, improves outcomes in women with heavily pretreated metastatic triple-negative breast cancer.
Empowering the Immune System
Growing from Embarrassment to Admiration of My Mother’s Breast Cancer
Funding for Cancer Research: Hope in a State of Fear
Healing Through Advocacy and Self-Discovery After AML Diagnosis